UY29352A1 - 5-fenilpirimidinas i sustituidas en terapeutica - Google Patents

5-fenilpirimidinas i sustituidas en terapeutica

Info

Publication number
UY29352A1
UY29352A1 UY29352A UY29352A UY29352A1 UY 29352 A1 UY29352 A1 UY 29352A1 UY 29352 A UY29352 A UY 29352A UY 29352 A UY29352 A UY 29352A UY 29352 A1 UY29352 A1 UY 29352A1
Authority
UY
Uruguay
Prior art keywords
therapeutics
substituted
replaced
phenyl pyrimidines
carry
Prior art date
Application number
UY29352A
Other languages
English (en)
Inventor
Dr Thomas Grote
Dr Bernd Muller
Joachim Rheinheimer
Dr Barbara Nave
Dr Frank Schieweck
Dr Anja Schwogler
Dr Thorsten Jabs
Dr Carsten Blettner
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of UY29352A1 publication Critical patent/UY29352A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a 5-fenilpirimidinas I sustituídas cuyos grupos sustituyentes X e Y son tales como se describen en la Memoria Descriptiva; y en donde el radical pirimidina puede llevar un radical diferente de hidrógeno en la posición 2 y en donde el anillo fenilo puede no estar sustituído o puede llevar de 1 a 5 radicales L que son diferentes de hidrógeno, y las sales farmacéuticamente aceptables de 5-fenilpirimidinas sustituídas para usar en terapéutica, en particular en terapéutica o tratamiento de enfermedades cancerosas.
UY29352A 2005-01-31 2006-01-31 5-fenilpirimidinas i sustituidas en terapeutica UY29352A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05001955 2005-01-31

Publications (1)

Publication Number Publication Date
UY29352A1 true UY29352A1 (es) 2006-08-31

Family

ID=34933530

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29352A UY29352A1 (es) 2005-01-31 2006-01-31 5-fenilpirimidinas i sustituidas en terapeutica

Country Status (19)

Country Link
US (1) US20080146593A1 (es)
EP (1) EP1845991A2 (es)
JP (1) JP2008528535A (es)
KR (1) KR20070104893A (es)
CN (1) CN101111250A (es)
AR (1) AR054220A1 (es)
AU (1) AU2006208621B2 (es)
BR (1) BRPI0607108A2 (es)
CA (1) CA2595958A1 (es)
EA (1) EA014098B1 (es)
IL (1) IL184375A0 (es)
MX (1) MX2007008397A (es)
NZ (1) NZ556448A (es)
PE (1) PE20061042A1 (es)
TW (1) TW200637556A (es)
UA (1) UA87895C2 (es)
UY (1) UY29352A1 (es)
WO (1) WO2006079556A2 (es)
ZA (1) ZA200707315B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110144140A1 (en) * 2006-09-07 2011-06-16 Eriksen Birgitte L Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
TW200836741A (en) * 2007-01-11 2008-09-16 Basf Ag 2-substituted pyrimidines I in therapy
KR100936278B1 (ko) * 2007-12-14 2010-01-13 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는 피리미딘 유도체또는 이의 약학적으로 허용가능한 염을 유효성분으로함유하는 암 예방 및 치료용 조성물
AU2009282567B2 (en) * 2008-08-20 2014-10-02 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
CN111065635B (zh) * 2018-01-04 2022-07-22 无锡安万生物科技有限公司 作为mth1抑制剂的新型嘧啶衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006235A (en) * 1973-03-23 1977-02-01 Burroughs Wellcome Co. Treating CNS lymphoma
GB8314643D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Pyrimidine derivatives
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9700664D0 (en) * 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
BR0207975A (pt) * 2001-03-15 2004-06-15 Basf Ag Composto, processo para preparar 5 fenilpiridinas, produto intermediário, agente adequado para combater fungos nocivos fitopatogênicos, e, processo para combater fungos nocivos fitopatogênicos
US6887875B2 (en) * 2001-06-12 2005-05-03 Neurogen Corporation 2,5-diarypyrimidine compounds
IL161893A0 (en) * 2001-11-19 2005-11-20 Basf Ag 5-Phenylpyrimidines, agents comprising the same, method for production and use thereof
ATE428705T1 (de) * 2002-02-21 2009-05-15 Basf Se 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
AU2003249484A1 (en) * 2002-07-22 2004-02-09 Orchid Chemicals And Pharmaceuticals Ltd Novel bio-active molecules
US7371758B2 (en) * 2003-03-13 2008-05-13 National Science & Technology Development Agency Antimalarial pyrimidine derivatives and methods of making and using them
US20070054929A1 (en) 2003-05-20 2007-03-08 Basf Aktiengesellschaft 2-Substituted pyrimidines
CA2532568A1 (en) * 2003-07-24 2005-03-03 Basf Aktiengesellschaft 2-substituted pyrimidines
JP2007506746A (ja) * 2003-09-24 2007-03-22 ワイス・ホールディングズ・コーポレイション 抗癌剤としての５−アリールピリミジン類
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
DE102004003493A1 (de) * 2004-01-23 2005-08-11 Bayer Cropscience Ag 5-Phenylpyrimidine
JP2008505957A (ja) * 2004-07-14 2008-02-28 ビーエーエスエフ　アクチェンゲゼルシャフト ２−置換ピリミジン、その調製方法および有害菌類を防除するためのその使用

Also Published As

Publication number Publication date
EP1845991A2 (en) 2007-10-24
EA014098B1 (ru) 2010-08-30
BRPI0607108A2 (pt) 2010-03-09
KR20070104893A (ko) 2007-10-29
TW200637556A (en) 2006-11-01
WO2006079556A2 (en) 2006-08-03
WO2006079556A3 (en) 2006-09-21
JP2008528535A (ja) 2008-07-31
IL184375A0 (en) 2007-10-31
CA2595958A1 (en) 2006-08-03
AU2006208621B2 (en) 2011-08-11
ZA200707315B (en) 2008-11-26
UA87895C2 (en) 2009-08-25
CN101111250A (zh) 2008-01-23
MX2007008397A (es) 2007-09-07
AU2006208621A1 (en) 2006-08-03
US20080146593A1 (en) 2008-06-19
PE20061042A1 (es) 2006-11-20
NZ556448A (en) 2010-12-24
AR054220A1 (es) 2007-06-13
EA200701582A1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
ECSP11011534A (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PA8632701A1 (es) Compuestos terapeuticos
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
CR9929A (es) Nuevos compuestos
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
CO6612228A2 (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
CU24087B1 (es) Compuestos de carbazol
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
UY31236A1 (es) Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]-piridazina, su preparacion y su aplicacion en terapéutica
TW200509892A (en) Novel aminobenzophenone compounds
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
UY29352A1 (es) 5-fenilpirimidinas i sustituidas en terapeutica
ECSP109964A (es) Pirimidinas bicíclicas fusionadas
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
DE602006014273D1 (de) Pyrazoloä3 , 4-düazepinderivate als histamin-h3-antagonisten
UY35393A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
ATE396970T1 (de) 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri